The EV-302 study1 marks a pivotal leap in the management of advanced urothelial carcinoma, setting a new benchmark for frontline therapy. Enfortumab vedotin plus pembrolizumab is the first combination therapy that has ever outperformed standard chemotherapy. The degree of benefit and the reported safety profile should make this combination a first-choice option for most patients with advanced-stage urothelial carcinoma.
Med (New York, N.Y.). 2024 Jun 14 [Epub]
Joaquim Bellmunt, Rosa Nadal
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Hospital del Mar Research Institute Lab (IMIM), Barcelona, Spain. Electronic address: ., National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.